Home Science & Medicine Immunotherapy

Immunotherapy

Feature articles about current research in immunology that has significant impact or impact potential on thoracic oncology.

Takeaways from KEYNOTE-021 and IMpower 150 on Combination Chemotherapy and Checkpoint Inhibition in NSCLC

By Hossein Borghaei, MS, DO The role of checkpoint inhibitors in the management of recurrent or metastatic NSCLC is now well established. For patients who...

Immunotherapy Adverse-Event Treatment Resource Guide

The Nurse and Allied Health Professionals Committee, which consist of clinicians and researchers from around the world, identified the need for an evidence-based guideline...

Management of Immunotherapy Toxicity in NSCLC

By Beth Eaby-Sandy, MSN, CRNP When I started in thoracic medical oncology 15 years ago, we just had chemotherapy, and patient education was focused and...

Exploring the Potential of Immuno-oncology Combination Therapy

By Cynthia L. Kryder, MS, CCC-Sp Editor Note: The article is part of a newly launched ongoing series about immunooncology (IO) combination therapy, future articles...

The CRISPR-Cas9 Toolkit: Moving From Bench to Bedside

By Cynthia L. Kryder, MS Decades of immunology research have shown that it is possible to harness the power of the immune system to fight...

PD-L1 Blueprint Project

By Fred R. Hirsch, MD, PhD In the new era of immunotherapy in thoracic cancer, evaluating PD-L1 status remains a clinical challenge. In recognition of...

Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A New Paradigm Post-IASLC WCLC...

By Melody Watson The first plenary session on the last day of IASLC WCLC 2016 covered one of the most exciting areas in NSCLC research...

Changing Landscape of Front-line Immunotherapy

By Naiyer A. Rizvi The rapid development of anti-PD-1 and PD-L1 antibodies in cancer underscores the tremendous impact they have had on the cancer landscape...

PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting...

Update on Checkpoint Inhibitors in Lung Cancer

By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology,...

Meeting News